Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527613 | 1.00 | BACE1 (0.49) | BACE1BACE2 | |
| SCHEMBL12789116 | 0.88 | BACE2 (0.45) | BACE1BACE2 | |
| SCHEMBL4074340 | 0.84 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL6521625 | 0.82 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL1978209 | 0.81 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL1978212 | 0.81 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL6521619 | 0.79 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL6521621 | 0.79 | BACE1 (0.47) | BACE1BACE2 | |
| SCHEMBL27876351 | 0.78 | BACE1 (0.39) | BACE1BACE2 | |
| SCHEMBL2586144 | 0.78 | BACE1 (0.45) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130096107-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096107-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | BACE1 2843/4885BACE2 1846/4885 |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | BACE1 2843/4885BACE2 1846/4885 |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | BACE1 2843/4885BACE2 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.